Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck

OncoTargets and Therapy

Volumn 2, Issue , 2009, Pages 243-250

  Perri, Francesco ^a   Longo, Francesco ^a   Ionna, Franco ^a   Caponigro, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cetuximab; Head and neck cancer; Locally advanced; Recurrent metastatic

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLACEBO; PROTEIN KINASE B; TAXANE DERIVATIVE;

ADJUVANT THERAPY; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CONTINUOUS INFUSION; DERMATITIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEEDING APPARATUS; FEVER; GENE CONTROL; HEAD AND NECK CARCINOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; LARYNX DISORDER; LEUKOPENIA; LOADING DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHARYNX DISEASE; PROGNOSIS; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR MODEL; TUMOR REGRESSION; VOMITING;

EID: 77953386064     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br J Cancer. 2004;91:418-424. (Pubitemid 39093557)
2. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666-2672. (Pubitemid 46622088)
3. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824-832. (Pubitemid 28280548)
4. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinoma. J Clin Oncol. 2006;24:4170-4176. (Pubitemid 46622295)
5. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cell cancer. J Clin Oncol. 2007;25:2164-2170. (Pubitemid 46954638)
6. Bandrés E, Barricarte R, Cantero C, et al. Epidermal growth factor receptor (EGFR) polymorphisms and survival in head and neck cancer patients. Oral Oncol. 2007;43:713-719. (Pubitemid 47058373)
7. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18:904-914. (Pubitemid 30106623)
8. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001;7:1204-1213. (Pubitemid 32708671)
9. NCCN Clinical Practice Guidelines in Oncology. Latest update date and version number 2007-2008. [Cited July 27, 2009]. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
10. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol. 2005;23:8646-8653. (Pubitemid 46211507)
11. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866-2872. (Pubitemid 46630587)
12. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127.
13. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578-5587. (Pubitemid 46300152)
14. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum refractory metastatic and or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568-5576. (Pubitemid 46300151)
15. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter, phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177. (Pubitemid 46954639)
16. Knoedler M, Gauler TC, Matzdorff A, et al. Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer [abstract]. J Clin Oncol. 2008;26(Suppl 15):6066.
17. Buentzel J, De Vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol. 2007;25(Suppl 18):6077.
18. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949-955.
19. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952. (Pubitemid 38580197)
20. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-146. (Pubitemid 18168463)
21. Ng CE, Keng PC, Sutherland RM. Characterization of radiation sensitivity of human squamous carcinoma A431 cells. Br J Cancer. 1987;56:301-307. (Pubitemid 17158819)
22. Peter RU, Beetz A, Ried C, Michel G, van Beuningen D, Ruzicka T. Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res. 1993;136:65-70. (Pubitemid 23342601)
23. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiation induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15:1191-1197. (Pubitemid 27429622)
24. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modaliy therapy of A431 human epidermoid cancer using anti-EGFR antbody C225 and radiation. Cancer Biother Radiopharm. 1999;14:451-463.
25. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2009;19:3234-3243.
26. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. (Pubitemid 43209104)
27. Curran D, Giralt J, Harari PM. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;10:2191-2198. (Pubitemid 46954642)
28. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locoregionally advanced squamous cell head and neck cancer: a pilot phase II study of a new combined modality paradigm. J Clin Oncol. 2006;7:1072-1078.
29. Merlano MC, Numico G, Russi EG, et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study [abstract]. J Clin Oncol. 2007;25(Suppl 18):6043.
30. Kuhnt T, Sandner A, Wendt TG, et al. Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a phase I dose escalation trial [abstract]. J Clin Oncol. 2008;26(Suppl 15):6029.
31. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695-1704. (Pubitemid 350005151)
32. Posner MR, Hershock DM, Blajman CR, et al; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705-1715.
33. Kies MS, Garden AS, Holsinger C, et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin and cetuximab for squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol. 2006;24(Suppl 18):5520.
34. Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of C225 combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, and radiation for Stage III/IV operable squamous cancer of the head and neck: A trial of the Eastern Cooperative Oncology Group (ECOG E2303) [abstract]. J Clin Oncol. 2007;25(Suppl 18):6015.
35. Tishler RB, Posner MR, Wirth LJ, et al. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study [abstract]. J Clin Oncol. 2008;26(Suppl 15):6001.
36. Kuperman DI, Nussenbaum B, Thorstad W, Haughey B, Lewis J, Adkins D. Retrospective analysis of the addition of cetuximab to induction chemotherapy (IC) with docetaxel, cisplatin, and 5-fluorouracil (TPF-C) for locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) [abstract]. J Clin Oncol. 2007;25(Suppl 18):6072.
37. Argiris AE, Karamouzis MV, Heron DE, et al. Phase II trial of docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (RT), P, and E in locally advanced head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol. 2007;25(Suppl 18):6051.
38. Langer J, Lee JW, Patel UA, et al. Preliminary analysis of ECOG 3303: Concurrent radiation, cisplatin and cetuximab in unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2008;26(Suppl 15):6006.
39. Bonnin N, Ceruse P, Bachelot T, et al. Efficacy of neoadjuvant TPF (nTPF; docetaxel, T; cisplatin, P; 5FU) in nonselected patients (pts) with head and neck cancer and subsequent radiotherapy (RT) combined with chemotherapy (CT) or cetuximab (Cx) [abstract]. J Clin Oncol. 2008;26(Suppl 15):6074.
40. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10(19):6487-6501. (Pubitemid 39346544)
41. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004;64(15):5355-5362. (Pubitemid 39006556)
42. Kies S , Gibson MK , Kim SW, et al. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis. J Clin Oncol. 2008;26(Suppl 15):6072.
43. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med. 2008;359:1757-1765.
44. Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM. Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope. 1994;104:1337-1347. (Pubitemid 24346961)
45. Rathcke IO, Gottschlinch S, Görögh T, Lippert BM, Werner JA. Incidence of point mutations in Ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head and neck region. Laryngorhinootologie. 1996;75:465-470. (Pubitemid 26294808)